Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

28.52
-0.2000-0.70%
Post-market: 28.620.1000+0.35%19:23 EDT
Volume:33.63M
Turnover:964.44M
Market Cap:162.16B
PE:37.53
High:28.95
Open:28.79
Low:28.52
Close:28.72
52wk High:29.21
52wk Low:23.62
Shares:5.69B
Float Shares:5.64B
Volume Ratio:1.09
T/O Rate:0.60%
Dividend:1.72
Dividend Rate:6.03%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.90
PE(LYR):20.90

Loading ...

NYSE Most Active Issues

Dow Jones
·
1 hour ago

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
2 hours ago

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

THOMSON REUTERS
·
Sep 29

Pfizer Gets Tax Penalty of 12.6 Million Rupees

Reuters
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29

How Investors May Respond To Pfizer (PFE) ESMO Cancer Data Showcase

Simply Wall St.
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit

Reuters
·
Sep 29

Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Pfizer to Present Phase 3 SigVie-002 Survival Data for Sigvotatug Vedotin in Previously Treated NSCLC at ESMO 2026

Reuters
·
Sep 28

Pfizer (PFE) Bets Big on RSV and Cancer Care

TIPRANKS
·
Sep 26

NYSE Most Active Issues

Dow Jones
·
Sep 26

Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study

TIPRANKS
·
Sep 26

Pfizer’s RSV Revaccination Trial Targets Durable Booster Revenue in High‑Risk Adults

TIPRANKS
·
Sep 26

C4 Therapeutics Says Cemsidomide-Elranatamab Phase 1b Trial Clears 75 Μg Dose as Safe in Multiple Myeloma

Reuters
·
Sep 25

Moderately bullish activity in Pfizer with shares up 0.9%

TIPRANKS
·
Sep 25